
Contrast developer Guerbet has received approval to market its Vectorio contrast media kit in Canada for imaging of hepatocellular carcinoma (HCC).
A mixing and injection system for administering Guerbet's Lipiodol Ultra Fluid Injection, Vectorio facilitates imaging of liver tumors in adults with known HCC during interventional oncology procedures, according to the vendor.